Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation
- PMID: 35833301
- PMCID: PMC9614524
- DOI: 10.3324/haematol.2022.281053
Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation
Figures


Similar articles
-
Analysis of 6q deletion in Waldenstrom macroglobulinemia.Eur J Haematol. 2007 Sep;79(3):244-7. doi: 10.1111/j.1600-0609.2007.00903.x. Epub 2007 Jul 26. Eur J Haematol. 2007. PMID: 17655703
-
6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance.Cancer Genet Cytogenet. 2006 Sep;169(2):150-3. doi: 10.1016/j.cancergencyto.2006.04.009. Cancer Genet Cytogenet. 2006. PMID: 16938573
-
Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion.Biomed Res Int. 2018 Oct 4;2018:6728128. doi: 10.1155/2018/6728128. eCollection 2018. Biomed Res Int. 2018. PMID: 30402490 Free PMC article.
-
Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia.Curr Opin Hematol. 2007 Jul;14(4):369-74. doi: 10.1097/MOH.0b013e3281ddb2b8. Curr Opin Hematol. 2007. PMID: 17534163 Review.
-
Waldenström macroglobulinemia with karyotypic aberrations involving both homologous 6q.Cancer Genet Cytogenet. 2001 Jan 15;124(2):137-9. doi: 10.1016/s0165-4608(00)00334-4. Cancer Genet Cytogenet. 2001. PMID: 11172905 Review.
Cited by
-
Waldenström Macroglobulinemia in Very Elderly (≥75-year-old) Patients: A 33-year-retrospective Cohort Study in an Italian University Hospital.Hemasphere. 2023 Oct 3;7(10):e964. doi: 10.1097/HS9.0000000000000964. eCollection 2023 Oct. Hemasphere. 2023. PMID: 37799344 Free PMC article. No abstract available.
-
Optimal use of BTK inhibitors in Waldenström's macroglobulinemia: combination or single drug approach?Ther Adv Hematol. 2024 Dec 23;15:20406207241308771. doi: 10.1177/20406207241308771. eCollection 2024. Ther Adv Hematol. 2024. PMID: 39734591 Free PMC article. Review.
-
Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study.Haematologica. 2024 Jan 1;109(1):325-330. doi: 10.3324/haematol.2023.283141. Haematologica. 2024. PMID: 37584289 Free PMC article. No abstract available.
-
Patients with Waldenström macroglobulinemia have impaired platelet and coagulation function.Blood Adv. 2024 Nov 12;8(21):5542-5555. doi: 10.1182/bloodadvances.2024014190. Blood Adv. 2024. PMID: 39207869 Free PMC article.
-
Genomic and immune profiling of prognostic risk groups in IgM gammopathy reveals novel biomarkers beyond MYD88 L265P.Front Immunol. 2025 Jul 1;16:1604089. doi: 10.3389/fimmu.2025.1604089. eCollection 2025. Front Immunol. 2025. PMID: 40666506 Free PMC article.
References
-
- Hunter ZR, Xu L, Yang G, et al. . The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637-1646. - PubMed
-
- Krzisch D, Guedes N, Boccon-Gibod C, et al. . Cytogenetic and molecular abnormalities in Waldenström’s macroglobulinemia patients: correlations and prognostic impact. Am J Hematol. 2021;96(12):1569-1579. - PubMed
-
- Pophali PA, Bartley A, Kapoor P, et al. . Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. Br J Haematol. 2019;184(6):1014-1017. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources